Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allergy immunotherapy - Roxall Medizin

Next Previous
Drug Profile

Allergy immunotherapy - Roxall Medizin

Alternative Names: Allergovac depot Olea; Allergovac grass pollen; Allergovac grass pollen depot; Allergovac Poliplus; BIA 14-2964; Olea europaea extract - Bial; PHLEUM PRATENSE POLLEN; SLI-RX-PHL; SULGEN Spray Dermatophagoides pteronyssinus; SULGEN Spray Phleum pratense

Latest Information Update: 14 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bial
  • Developer BIAL; ROXALL Medizin GmbH
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Allergic rhinoconjunctivitis
  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 05 Sep 2025 Roxall Medizin GmbH plans a phase II/III trial for Allergic rhinoconjunctivitis and Allergic Rhinitis in Germany, Ukraine, Turkey and Kazakhstan (Sublingual) in October 2025 (CTIS2024-517524-18-00)
  • 09 Feb 2024 Roxall Medizin GmbH completes a phase II trial in Seasonal allergic rhinitis (In adults) in Germany (Sublingual) (EudraCT2021-002881-42)
  • 09 Feb 2024 Roxall Medizin GmbH completes a phase II trial in Allergic rhinoconjunctivitis (In adults) in Germany (Sublingual) (EudraCT2021-002881-42)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top